Critical Care Diagnostics Market Size & Share, by Type (Routine & Special Chemistry, Flow Cytometry, Hematology, Immunoproteins, Microbial & Infectious Disease, Coagulation Testing); Product (Glucose Monitoring, Cardiometabolic Monitoring, Infectious Disease, Coagulation Monitoring, Cancer Markers, Hematology, Pregnancy and Fertility, Cholesterol, Drugs-Of-Abuse & Fecal Occult Testing Kits) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5813
  • Published Date: Mar 05, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024 - 2036

Critical Care Diagnostics Market size is poised to cross USD 3 Billion by the end of 2036, growing at a CAGR of 6% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of critical care diagnostics was USD 1 Billion. The reason behind the growth is due to the growing burden of cancer across the globe. For instance, there are an estimated 0.7 million new instances of cancer annually, indicating a constant increase in poor diet, alcohol use, smoking, physical inactivity, air pollution, and other noncommunicable illnesses, which are exacerbated by aging and population expansion.

According to the World Health Organization (WHO), it is anticipated that there will be over 35 million new cases of cancer in 2050, a 77% increase over the projected 20 million cases in 2022.

The growing development of quick diagnostic tools is believed to fuel the critical care diagnostics market growth. Without the need for complex equipment, the latest generation of miniaturized biosensor technologies for point-of-care testing has produced a more sensitive, dependable, quick, and economical detection procedure, which has benefited the clinical management of numerous applications, including pathology, drug discovery, and food safety.


Critical Care Diagnostics Market
Get more information on this report: Request Free Sample PDF

Critical Care Diagnostics Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising Geriatric Population – A rising percentage of severely ill patients admitted to intensive care units are adult individuals who have complex medical and social needs, and who survive serious illnesses such as sepsis or respiratory failure. For instance, just between 2000 and 2050, the percentage of adults 80 and older worldwide will rise to over 4%.
  • Growing Prevalence of Cardiovascular Disorders- The level of risk can be ascertained by undergoing a cardiovascular risk assessment which usually takes a combination of imaging, cardiac monitoring, and blood testing to diagnose a heart condition. As per the World Health Organization (WHO), globally, cardiovascular diseases (CVDs) account for 17.9 million deaths annually, making them the leading cause of death.
  • Surging Incidence of Lifestyle-related Disorders- Type 2 diabetes and high blood pressure are a few lifestyle diseases that share risk factors with extended exposure to three modifiable lifestyle factors and involve enhanced diagnostics and medication, as well as intense disability management and extended care.

Challenges

  • Exorbitant Cost of Critical Care Diagnostics- Intensive care units, or ICUs, are expensive facilities owing to the admission of patients with complex and life-threatening illnesses, the utilization of costly instruments and equipment, and the increased staffing ratio per patient.
  • It's common to characterize critical care as costly treatment since these treatments are labor-intensive, and they have an overabundance of patients, owing to their extended hospital stays, survivors of critical care may incur higher hospital costs. As ICU survivors depart the hospital, their experience in intensive care may leave them with ongoing, long-term health issues, and in lower-income nations, patients typically pay out-of-pocket for their visits since critical care costs are also frequently not fully covered by health insurance systems.
  • Resource Constraints in many low-income regions such as a lack of skilled professionals
  • Inadequate infrastructure in remote areas can impact the delivery of critical care diagnostics

Critical Care Diagnostics Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~6%

Base Year Market Size (2023)

~ USD 1 Billion

Forecast Year Market Size (2036)

~ USD 3 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Critical Care Diagnostics Segmentation

Type (Routine & Special Chemistry, Flow Cytometry, Hematology, Immunoproteins, Microbial & Infectious Disease, Coagulation Testing)

The immunoproteins segment in the critical care diagnostics market is estimated to gain a robust revenue share of 37% in the coming years. Immunoprotein diagnostic testing is defined as the process of examining particular proteins produced by the immune system such as cytokines, antigens, or antibodies in the body to examine illnesses associated with particular proteins, including immunoglobulin, pre-albumin, and others. Immunoproteins are blood proteins that are essential to the immune system's operation and perform a crucial part in the diagnosis of cancer, and infectious diseases, and are extremely important since they provide insight into the immune system's resilience and help diagnose autoimmune disorders. The use of laboratory and patient-explicit assays is part of immunoprotein diagnostic testing which is based on the particular protein levels that were abnormal as well as whether the levels were too high or low.

In addition, the process of identifying and frequently characterizing the causative agent of an infectious disease is known as infectious disease diagnostics which uses methods such as molecular diagnostics, biochemical testing, microscopy, and microbial culture. Besides this, blood and blood diseases are studied in hematology which also involves an examination of hematopoiesis.

End-User (Operation Room, Intensive Care Unit, Emergency Rooms)

The emergency rooms segment in the critical care diagnostics market is set to garner a notable share shortly. The primary focus of an emergency department and critical care unit is the patient's health; therefore, the emergency room treats patients with injuries that are immediately life-threatening and circumstances that call for rapid, emergency care. Emergency physicians should concentrate on providing patients who are seriously injured or unwell with prompt care since if they wait longer, they risk organ failure, and other negative consequences.

Our in-depth analysis of the global market includes the following segments:

          Type

  • Routine & Special Chemistry
  •  Flow Cytometry
  •  Hematology
  •  Immunoproteins
  •  Microbial & Infectious Disease
  • Coagulation Testing

          End-User

  • Operation Room
  •  Intensive Care Unit
  •  Emergency Rooms

          Product

  • Glucose Monitoring Kits
  • Cardiometabolic Monitoring Kits
  • Infectious Disease Testing Kits
  • Coagulation Monitoring Kits
  •  Cancer Markers Testing Kit
  • Hematology Testing Kits
  •  Pregnancy and Fertility Testing Kits
  • Cholesterol Test Strips
  •  Drugs-Of-Abuse Testing Kits
  •  Fecal Occult Testing Kits

          Prescription Mode

  • Prescription-Based Testing Kits
  • OTC Testing Kits

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Critical Care Diagnostics Industry - Regional Synopsis

North American Market Forecast

The critical care diagnostics market in North America is predicted to hold the largest revenue share of 45% by 2036 impelled by the growing investment in healthcare. The yearly growth rate of U.S. healthcare spending is currently over 1% higher than the GDP, and the amount spent on healthcare in the United States will total around USD 6 trillion by 2028, or over 15% of GDP. Particularly, in 2022, US healthcare spending increased by more than 4%. As a result, hospitals hugely investing in advanced diagnostic technologies, leading to an increase in accessibility to advanced imaging systems, and point-of-care testing devices necessary in critical care settings.

APAC Market Statistics

The Asia Pacific critical care diagnostics market is estimated to the second largest revenue share, during the forecast period, led by the rising medical tourism. India has become a significant medical tourism hub in recent years, owing to its low-cost treatments, presence of highly skilled and specialized medical professionals, and state-of-the-art medical facilities. For instance, over the past ten years, medical tourism has brought in over USD 7 billion for India; in the next ten years, it is anticipated to reach around USD 43 billion.

Research Nester
Critical Care Diagnostics Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Critical Care Diagnostics Landscape

top-features-companies
    • Abbott
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • F. Hoffmann-La Roche Ltd
    • Danaher
    • BD
    • EKF Diagnostics
    • bioMérieux, Inc.
    • Siemens Healthcare Private Limited
    • Chembio Diagnostics, Inc.
    • Bayer AG

In-the-news

In The News

  • Abbott obtained approval from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life support system, CentriMag Blood Pump for use with the CentriMag System a type of life support for people whose heart and lungs are not working, and to enable physicians more time to make critical care decisions for their patients.
  • F. Hoffmann-La Roche Ltd. announced the launch of the next-generation qPCR system, LightCycler PRO System to enable a portfolio of more than 200 LightMix Modular research assays, and to meet clinical needs in molecular diagnostics and tackle public health issues in addition to enabling users to create their tests.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5813
  • Published Date: Mar 05, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing burden of cancer across the globe and the growing development of quick diagnostic tools are the major factors driving the growth of the market.

The market size of Critical Care Diagnostics is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2024-2036.

The major players in the market are F. Hoffmann-La Roche Ltd, Danaher, BD, EKF Diagnostics, bioMérieux, Inc., Siemens Healthcare Private Limited, Chembio Diagnostics, Inc., Bayer AG, and others.

The immunoproteins segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Critical Care Diagnostics Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying